Related Experiment Video

Updated: Aug 24, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

Clifford D Mol1, Douglas R Dougan, Thomas R Schneider

  • 1Syrrx, Inc., San Diego, California, 92121, USA. clifford.mol@syrrx.com

The Journal of Biological Chemistry
|May 5, 2004
PubMed

Insights

Researchers reveal how c-Kit kinase autoinhibition works, crucial for understanding cancer. This discovery aids in designing targeted therapies for c-Kit driven cancers.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Oncology

Background:

  • The c-Kit receptor protein-tyrosine kinase is vital in normal cell regulation.
  • Deregulated c-Kit kinase activity is linked to human cancer development.
  • The autoinhibitory mechanism of c-Kit remains incompletely understood.

Purpose of the Study:

  • To elucidate the structural mechanism of c-Kit kinase autoinhibition.
  • To compare the structures of autoinhibited and active c-Kit kinase.
  • To understand how STI-571 (Imatinib) interacts with c-Kit.

Main Methods:

  • X-ray crystallography to determine the 3D structure of c-Kit kinase.
  • Analysis of native c-Kit kinase in an autoinhibited conformation (1.9-A resolution).
  • Analysis of c-Kit kinase in complex with STI-571 (1.6-A resolution).

Main Results:

  • The crystal structure of native c-Kit kinase in an autoinhibited state was determined.
  • The juxtamembrane domain was found to stabilize autoinhibition by inserting into the kinase-active site.
  • STI-571 binding was shown to disrupt the natural autoinhibition mechanism of c-Kit.

Conclusions:

  • The study provides a structural basis for c-Kit kinase autoinhibition.
  • Understanding this mechanism is key for developing targeted cancer therapies.
  • Results facilitate structure-guided design of inhibitors for both active and autoinhibited c-Kit conformations.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...